Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2021

View Archived Issues

Surface Ophthalmics initiates phase II trial of SURF-200 for acute dry eye

In vivo data on IHL-675A supports expansion of indications to include COPD and asthma

Thrombin trivalent inhibitors inspired by native peptidic inhibitors from hematophagous arthropods

CD22 is a potential target for CAR T-cell therapy in LBCL after failure of autologous CAR19 therapy

FDA places clinical hold on phase IIa study of SPR-720

Ono Pharmaceutical divulges KDM5A inhibitors

Kymera Therapeutics patents CRBN inhibitors

Pfizer presents new TLR agonists

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Good T Cells patents molecules for treating immune checkpoint inhibitor-resistant cancer

Phase III KESTREL study of Imfinzi in HNSCC does not meet its primary or secondary endpoints

SerpinPC found useful in patients with severe hemophilia

FDA approves phase I/IIa study of HDP-101 in multiple myeloma

Single-cell resolution reveals cell type, targets, for neuroblastoma

Updated patient eligibility and first-in-human data for BAY-2599023

Korean MFDS grants conditional marketing authorization for Regkirona for COVID-19

Bevacizumab shows potential benefit in COVID-19 patients

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Phase I/II results for TAK-754 gene therapy in severe hemophilia A

Alphamab initiates phase I/II study of KN-046 with donafenib in HCC

Safety, immune responses reported for SARS-CoV-2 vaccine BBV-152 in clinical trial

PCOS passed on in the epigenes

Preclinical data presented for GD2-B7H3 CART in metastatic neuroblastoma

FDA approves Breyanzi for relapsed or refractory large B-cell lymphoma

Phase I trial of IDE-397 for solid tumors with MTAP deletion cleared to begin in U.S.

FDA clears IND for phase I/II study of PBKR-03 for Krabbe disease

Sinovac reports phase III data on CoronaVac

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...